To elucidate the prognostic marker using amino acid PET imaging and signal transduction factors in brain tumor patients

To elucidate the prognostic marker using amino acid PET imaging and signal transduction factors in brain tumor patients - To elucidate the prognostic marker using amino acid PET imaging and signal transduction factors in brain tumor patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023933

Enrollment

Registered

2016-11-01

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumor (glioma)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)The patient undergoes MET PET/CT in Kindai University Hospital. (2)The patient is diagnosed as glioma with CT, MRI and other clinical findings at neurosurgery in Kindai University Hospital, and is needed to surgery or biospsy. (3)The age of the patient is over 20 age years. (4)The document about the agreement with participation of this study is obtained from patient.

Exclusion criteria

Exclusion criteria: (1)The patient has metastatic brain tumor, malignant lymphoma or other brain tumors and malignant tumors. (2)The glioma patient without treatment adaptation. (3)The document about the agreement with participation of this study is not obtained from patient. (4)Pregnant woman, possibility of the pregnancy woman, lactating woman. (5)The age of the patient is less than 20 age years. (6)The patient cannot undergo PET/CT examination because of serious complication (7)The doctor makes a judgement that the patient is not appropriate for participatingin this study.

Design outcomes

Primary

Measure	Time frame
To evaluate the optimal MET uptake parameter and signal transduction factor for prognosis of glioma patients.	—

Secondary

Measure	Time frame
To reveal whether we predict the expression of signal transduction factors and the degree of malignancy using MET uptake parameters. To investigate whether MET uptake and the expression of signal transduction factors have an influence on the management of therapy such as molecular target therapy in glioma patients. To reveal the relationship between amino acid metabolism and tumorgenesis of glioma using MET uptake, signal transduction factors, and clnicopathological factors.	—

Measure

Time frame

To reveal whether we predict the expression of signal transduction factors and the degree of malignancy using MET uptake parameters. To investigate whether MET uptake and the expression of signal transduction factors have an influence on the management of therapy such as molecular target therapy in glioma patients. To reveal the relationship between amino acid metabolism and tumorgenesis of glioma using MET uptake, signal transduction factors, and clnicopathological factors.

—

Countries

Japan

Contacts

Public ContactHayato Kaida

Kindai University Faculty of Medicine Department of Radiology

kaida@med.kindai.ac.jp072-366-0221

Outcome results